# Promise.

## The PROMISE Connection

**JULY 2025** 




#### Q: How can I know if my cancer has

The Doctor is In

spread while I'm still going through radiation treatment? A: Radiation focuses on treating a

specific area of the body, but it's natural to have questions about whether the cancer may be growing or moving elsewhere during this time. While you're going through radiation,

your care team may use a combination of tools to monitor how things are going: detect whether the cancer has spread beyond the original site. These are usually



- scheduled before, during, or after treatment, depending on your specific case. **Blood tests**, including PSA (prostate-specific antigen) levels if you're being treated for prostate cancer, can provide clues. Rising PSA levels during or after treatment
- may suggest that more evaluation is needed. Physical symptoms may also be important. New pain, fatigue, or other unexplained symptoms should always be shared with your doctor, as they might
- indicate changes worth looking into. It's important to know that some changes in how your body feels during treatment are normal and not necessarily a sign that the cancer has spread. But if there's ever a concern, your healthcare team can order additional tests or scans to check.

If you're unsure or feeling anxious, don't hesitate to ask your doctor questions directly. Have a question? PROMISE researchers Drs. Channing Paller and Heather Cheng, and

Genetic Counselor Justin Lorentz are here to help. Feel free to email your questions to pcctcpromise@mskcc.org While we may not be able to respond to every individual query, we'll gather common themes and provide answers.



### The CHANCES (Clonal HemAtopoeisis iN CancEr Survivors) Study, led by Fred

### Hutchison Cancer Center and the University of Washington, aims to understand

Predicting and Preventing Treatment-Related Blood Cancers

why some cancer survivors develop blood cancers like leukemia after treatment, especially from certain chemotherapies combined with PARP inhibitors. Researchers are inviting survivors of ovarian and other solid cancers to join. Participation includes:

 A small blood sample (collected at a convenient lab) Sharing treatment history every six months for 3 years

- Though individual results aren't returned, participants receive: A \$50 gift card after 6 months
  - Periodic study updates with overall findings

Your involvement could help predict—and prevent—these serious treatment-

- related complications.
- By joining this effort, you'll be helping protect and improve the health of future

cancer patients. Learn more: CHANCES Clinical Trial

Helping Families Understand Their Risk: OHSU Seeks Volunteers for **Prostate Cancer Genetic Study** 

The Knight Cancer Institute at OHSU is seeking individuals and families affected by prostate cancer to join a study on Cascade Genetic Testing (CGT).


make a difference for countless families.

#### When one person carries a cancer-related genetic mutation, close relatives may also be at risk. CGT offers them genetic testing and counseling to support informed health decisions.

This study examines the barriers families encounter when accessing CGT and seeks to enhance the process.

Participants receive free genetic testing and counseling, helping both their own families and others in the future. If you or a loved one has been affected by prostate cancer, your experience could

Learn more: Cascade Germline Genetic Testing in Families Study



How genetic test results can change over time—and what that means for you

Burcu Darst, PhD (Fred Hutchinson/University of Washington) explained how

#### How sharing genetic information with family can help them take action, too Watch the webinar recording here.

**HELD JULY 16, 2025** 

What It Means for You and Your Care Two leading experts broke down the role of ATM gene mutations in cancer:

and ongoing monitoring strategies.

Watch the mini-webinar here.

Voices of PROMISE

Dennis' Journey from a Terminal Prostate ancer Diagnosis to a

Decoding ATM Mutations in Prostate Cancer

Cathy Marshall, MD, MPH (Johns Hopkins) discussed the implications of ATM mutations for patient care, highlighting targeted treatments, genetic testing,

these mutations can influence cancer risk and progression.

- From Terminal Diagnosis to Triumph: How Dennis Voices of Promise. Found Hope Through Genetic Testing
- prostate cancer. Refusing to give up, he pursued innovative treatments, lifestyle changes, and a clinical trial that ultimately saved his life. Now 80, Dennis credits part of his survival to a free genetic test

PROMISE Registry.

Read Dennis'

full story here.

PROMISE by the Numbers

At just 53, Dennis was told he had 18 months to live after being diagnosed with aggressive, metastatic

through the PROMISE Registry, which revealed

remarkable response to therapy but also provided critical insights for his children and grandchildren.


His story is a powerful reminder of the role genetics

prostate cancer patients to consider enrolling in the

can play in cancer outcomes—and why he urges other

a CHEK2 mutation that not only explained his

# genetic tests completed



How to Reach Us

Mon. - Fri., 9 am to 5 pm EST

PROMISE Study Team

**Hours of Operation** 



that you are a participant in the PROMISE study. **Hours of Operation** Mon. – Fri., 6 am to 5 pm PST

participants are eligible

for long-term follow-up

support@color.com

Phone Number

(844) 352-6567

Email

**Email** pcctcpromise@mskcc.org

#### **Phone Number** (646) 449-3363

Promise.

www.prostatecancerpromise.org.